{"id":"covid19-mrna-vaccine","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL4650372","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This is achieved through the use of messenger RNA (mRNA) that encodes for a portion of the SARS-CoV-2 spike protein. Once the mRNA is taken up by cells, it is translated into the spike protein, which is then recognized by the immune system as foreign, triggering an immune response.","oneSentence":"The COVID19 mRNA vaccine works by instructing cells to produce a piece of a viral protein, triggering an immune response to the virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:29:11.493Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of COVID-19 disease caused by SARS-CoV-2 virus"}]},"trialDetails":[{"nctId":"NCT06585241","phase":"PHASE4","title":"A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2024-09-09","conditions":"SARS-CoV-2","enrollment":1144},{"nctId":"NCT05212610","phase":"PHASE4","title":"Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2022-03-21","conditions":"COVID-19, Corona Virus Infection","enrollment":137},{"nctId":"NCT07464314","phase":"PHASE1","title":"A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-03-09","conditions":"Influenza, Human+COVID-19","enrollment":225},{"nctId":"NCT04368728","phase":"PHASE2, PHASE3","title":"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2020-04-29","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":46969},{"nctId":"NCT05265065","phase":"PHASE3","title":"Evaluation of Full Versus Fractional Dose of COVID-19 Vaccine Given as a Booster for the Prevention of COVID-19 in Adults in Mongolia.","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-27","conditions":"COVID-19","enrollment":601},{"nctId":"NCT05392075","phase":"","title":"COVID-19 Breakthrough Infection in Fully Vaccinated People and in People Who Received a Booster Dose","status":"COMPLETED","sponsor":"Methodist Health System","startDate":"2023-03-15","conditions":"COVID-19 Pneumonia, COVID-19","enrollment":100},{"nctId":"NCT05283902","phase":"","title":"Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly","status":"COMPLETED","sponsor":"Federal University of Espirito Santo","startDate":"2022-03-19","conditions":"COVID-19, Vaccine Adverse Reaction, Vaccine-Preventable Diseases","enrollment":260},{"nctId":"NCT04649021","phase":"PHASE2","title":"Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2020-12-04","conditions":"SARS-CoV-2","enrollment":960},{"nctId":"NCT07279766","phase":"PHASE4","title":"Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tor Biering-Sørensen","startDate":"2025-12-11","conditions":"COVID-19","enrollment":285000},{"nctId":"NCT05876377","phase":"","title":"Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-10-23","conditions":"SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome","enrollment":1},{"nctId":"NCT07266558","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2025-11-26","conditions":"SARS-CoV-2","enrollment":30000},{"nctId":"NCT05397223","phase":"PHASE1","title":"A Study of Modified mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-24","conditions":"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus","enrollment":308},{"nctId":"NCT05672355","phase":"PHASE2","title":"A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-08-01","conditions":"Chronic Lymphocytic Leukemia, COVID-19 Infection","enrollment":80},{"nctId":"NCT07051031","phase":"PHASE4","title":"COVID-19 Reactogenicity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Marcel Curlin","startDate":"2025-10-01","conditions":"COVID-19","enrollment":1000},{"nctId":"NCT05415267","phase":"PHASE3","title":"Immunosuppression and COVID-19 Boosters","status":"RECRUITING","sponsor":"Kirby Institute","startDate":"2023-07-21","conditions":"COVID-19","enrollment":320},{"nctId":"NCT07408297","phase":"PHASE2","title":"Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda","status":"COMPLETED","sponsor":"Victoria Biomedical Research Institute","startDate":"2022-05-18","conditions":"COVID -19, SARS CoV 2 Infection","enrollment":1919},{"nctId":"NCT07280858","phase":"PHASE1, PHASE2","title":"A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.","status":"RECRUITING","sponsor":"SK Bioscience Co., Ltd.","startDate":"2026-01-28","conditions":"Healthy Participants, Sarbecovirus","enrollment":368},{"nctId":"NCT04977024","phase":"PHASE2","title":"SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"GeoVax, Inc.","startDate":"2021-09-27","conditions":"COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia","enrollment":63},{"nctId":"NCT07222384","phase":"PHASE3","title":"A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2025-10-30","conditions":"COVID-19, SARS-COV-2 Infection","enrollment":343},{"nctId":"NCT07390968","phase":"PHASE2","title":"Self-Amplifying mRNA COVID-19 Vaccine (LUNAR-COV19) Versus Comirnaty Vaccine in Adult Hematopoietic Cell Transplant Patients","status":"NOT_YET_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-09-01","conditions":"Hematopoietic and Lymphatic System Neoplasm","enrollment":56},{"nctId":"NCT05119855","phase":"PHASE3","title":"Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-03-28","conditions":"Papillomavirus Infections, Coronavirus Disease (COVID-19)","enrollment":165},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT06065176","phase":"PHASE4","title":"The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection","status":"COMPLETED","sponsor":"Sarang K. Yoon, DO, MOH","startDate":"2023-11-22","conditions":"COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection","enrollment":1188},{"nctId":"NCT05951920","phase":"NA","title":"Lymph Node Aspiration to Decipher the Immune Response of Beta-variant Recombinant Protein Booster Vaccine (VidPrevtyn Beta, Sanofi) Compared to a Bivalent mRNA Vaccine (Comirnaty Original/Omicron BA.4-5, BioNTech-Pfizer) in Adults Previously Vaccinated With at Least 3 Doses of COVID-19 mRNA Vaccine.","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-07-05","conditions":"COVID-19","enrollment":12},{"nctId":"NCT06503900","phase":"PHASE4","title":"Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2024-09-12","conditions":"Birth Outcomes, Safety, Adverse Event Following Immunization","enrollment":98},{"nctId":"NCT05077254","phase":"PHASE2","title":"COVID Protection After Transplant-Immunosuppression Reduction","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-12-06","conditions":"Kidney Transplant Recipients, Liver Transplant Recipients","enrollment":48},{"nctId":"NCT04872738","phase":"","title":"Patient Experiences With the COVID-19 Vaccination After Breast Cancer Treatment","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2021-05-07","conditions":"Breast Cancer Related Lymphedema, Covid19","enrollment":714},{"nctId":"NCT05658523","phase":"PHASE3","title":"COVID-19 Booster Study in Healthy Adults in Australia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Murdoch Childrens Research Institute","startDate":"2023-02-28","conditions":"COVID-19","enrollment":496},{"nctId":"NCT05330975","phase":"PHASE3","title":"A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-04-01","conditions":"Respiratory Syncytial Virus","enrollment":3317},{"nctId":"NCT06374394","phase":"PHASE3","title":"A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-04-29","conditions":"Respiratory Syncytial Virus Infections","enrollment":841},{"nctId":"NCT04760704","phase":"","title":"Covid-19 Vaccine Response in Elderly Subjects","status":"COMPLETED","sponsor":"University Hospital, Lille","startDate":"2021-02-18","conditions":"Covid19 Vaccine","enrollment":264},{"nctId":"NCT07300839","phase":"PHASE3","title":"A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-12-10","conditions":"COVID-19, SARS-COV-2 Infection","enrollment":25500},{"nctId":"NCT05827926","phase":"PHASE1, PHASE2","title":"A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-04-14","conditions":"SARS-CoV-2, Influenza","enrollment":1758},{"nctId":"NCT07069309","phase":"PHASE3","title":"A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2025-07-08","conditions":"COVID-19, SARS-COV-2 Infection","enrollment":760},{"nctId":"NCT06821126","phase":"PHASE1, PHASE2","title":"Study Comparing Safety and Immunogenicity of Intranasal COVID-19 Vaccine and mRNA Booster in Healthy Adults","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-05-09","conditions":"Healthy","enrollment":238},{"nctId":"NCT07287137","phase":"PHASE4","title":"Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study","status":"RECRUITING","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2025-11-12","conditions":"COVID -19, COVID - 19, COVID 19","enrollment":54},{"nctId":"NCT06279871","phase":"PHASE3","title":"Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2024-03-27","conditions":"COVID-19","enrollment":1514},{"nctId":"NCT04780659","phase":"PHASE4","title":"COVID-19 Vaccination of Immunodeficient Persons (COVAXID)","status":"COMPLETED","sponsor":"Karolinska University Hospital","startDate":"2021-02-23","conditions":"Covid19","enrollment":539},{"nctId":"NCT06831786","phase":"EARLY_PHASE1","title":"Immunogenicity of COVID-19 Vaccine Co-administration With Influenza Vaccine in Healthy Volunteers","status":"COMPLETED","sponsor":"Prince of Songkla University","startDate":"2024-03-01","conditions":"COVID - 19","enrollment":36},{"nctId":"NCT06694389","phase":"PHASE3","title":"Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-11-18","conditions":"COVID-19, Influenza","enrollment":2457},{"nctId":"NCT05584202","phase":"PHASE2","title":"Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants","status":"TERMINATED","sponsor":"ModernaTX, Inc.","startDate":"2022-09-30","conditions":"SARS-CoV-2","enrollment":68},{"nctId":"NCT05168813","phase":"PHASE2, PHASE3","title":"Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern","status":"COMPLETED","sponsor":"COVID-19 Prevention Network","startDate":"2021-12-01","conditions":"SARS-CoV-2 Infection, HIV Infections, COVID-19","enrollment":14237},{"nctId":"NCT05436834","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-06-21","conditions":"SARS-CoV-2","enrollment":1807},{"nctId":"NCT06923137","phase":"","title":"A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much Money People Spend on Healthcare for COVID-19","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-04-16","conditions":"COVID-19 SARS-CoV-2 Infection, COVID-19, COVID-19 Infection","enrollment":1},{"nctId":"NCT05032976","phase":"","title":"Korea Comirnaty Post-marketing Surveillance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-03-18","conditions":"COVID-19, Vaccines, Adverse Effects","enrollment":12000},{"nctId":"NCT06441968","phase":"PHASE1","title":"Safety and Immunogenicity Trial of MPV/S-2P SARS-CoV-2 Vaccine in Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-07-01","conditions":"COVID-19","enrollment":60},{"nctId":"NCT04955626","phase":"PHASE3","title":"To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2021-07-01","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":16372},{"nctId":"NCT07215520","phase":"PHASE2","title":"Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults","status":"RECRUITING","sponsor":"CastleVax Inc.","startDate":"2025-11-03","conditions":"COVID-19","enrollment":200},{"nctId":"NCT06742281","phase":"PHASE2","title":"A Phase 2b, Randomized, Double-blind, Active-controlled Study of Single Dose CVXGA Intranasal COVID-19 Vaccine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"CyanVac LLC","startDate":"2024-12-05","conditions":"COVID-19","enrollment":432},{"nctId":"NCT05960097","phase":"PHASE2","title":"A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-08-01","conditions":"SARS-CoV-2, COVID-19","enrollment":692},{"nctId":"NCT06672055","phase":"PHASE2","title":"A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vaxart","startDate":"2024-10-08","conditions":"SARS-CoV2, COVID-19","enrollment":10400},{"nctId":"NCT05289037","phase":"PHASE2","title":"COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-03-30","conditions":"COVID-19","enrollment":1270},{"nctId":"NCT06864143","phase":"PHASE2","title":"A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2025-03-07","conditions":"Influenza, SARS-CoV-2","enrollment":1320},{"nctId":"NCT04852978","phase":"PHASE2","title":"COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-04-29","conditions":"Healthy, Chronic Stable Illness","enrollment":295},{"nctId":"NCT05556720","phase":"PHASE3","title":"Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Monash University","startDate":"2022-12-01","conditions":"HIV, Organ Transplantation, Lymphoma, Non-Hodgkin","enrollment":960},{"nctId":"NCT06237049","phase":"PHASE2","title":"A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-01-31","conditions":"Influenza, Human, SARS-CoV-2 Infection, COVID-19","enrollment":644},{"nctId":"NCT06452654","phase":"PHASE4","title":"Anti-viral Action Against Type 1 Diabetes Autoimmunity","status":"RECRUITING","sponsor":"Technical University of Munich","startDate":"2024-05-08","conditions":"Diabetes Mellitus, Type 1","enrollment":2252},{"nctId":"NCT04762680","phase":"PHASE2, PHASE3","title":"Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-02-24","conditions":"COVID-19","enrollment":3159},{"nctId":"NCT04649151","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2020-12-09","conditions":"SARS-CoV-2","enrollment":4328},{"nctId":"NCT04969276","phase":"PHASE2","title":"Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-07-16","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":306},{"nctId":"NCT06680375","phase":"PHASE1","title":"A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-11-11","conditions":"COVID-19","enrollment":106},{"nctId":"NCT04798027","phase":"PHASE1, PHASE2","title":"Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-03-12","conditions":"COVID-19","enrollment":182},{"nctId":"NCT06038617","phase":"PHASE4","title":"Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2023-10-30","conditions":"Fever After Vaccination, Fever, Seizures Fever","enrollment":344},{"nctId":"NCT05000216","phase":"PHASE2","title":"COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-13","conditions":"Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris","enrollment":258},{"nctId":"NCT05571735","phase":"","title":"Immunogenicity of COVID-19 Vaccines in Tuberculosis Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2023-04-15","conditions":"Covid-19 Pandemics, Tuberculosis","enrollment":133},{"nctId":"NCT04761822","phase":"PHASE2","title":"COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-07","conditions":"SARS-CoV Infection, COVID-19, Allergic Reaction","enrollment":746},{"nctId":"NCT04297917","phase":"PHASE1","title":"First in Human Study of ChAdOx1-HBV in Healthy Participants and Participants With Chronic hepB Infection","status":"COMPLETED","sponsor":"Barinthus Biotherapeutics","startDate":"2019-02-10","conditions":"Hepatitis B, Healthy","enrollment":47},{"nctId":"NCT04932863","phase":"","title":"BNT162b2 Messenger Ribonucleic Acid (mRNA) Covid-19 Vaccine in Cancer Patients on Active Treatment","status":"COMPLETED","sponsor":"Ente Ospedaliero Ospedali Galliera","startDate":"2021-03-15","conditions":"Neoplasms, Cancer, Treatment-Related","enrollment":300},{"nctId":"NCT06189053","phase":"","title":"A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)","status":"ACTIVE_NOT_RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2022-04-30","conditions":"Myocarditis","enrollment":1500},{"nctId":"NCT06113692","phase":"","title":"A Study on the Clinical Course, Outcomes and Risk Factors of Myocarditis and Pericarditis After Moderna COVID-19 Vaccine","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-03-31","conditions":"Myocarditis, Pericarditis","enrollment":1169},{"nctId":"NCT04969263","phase":"PHASE2","title":"COVID-19 Protection After Transplant Pilot Study","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-10","conditions":"Kidney Transplant Recipients","enrollment":81},{"nctId":"NCT04848584","phase":"","title":"Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern California","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-05-15","conditions":"COVID-19","enrollment":1},{"nctId":"NCT05158140","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-12","conditions":"Pneumococcal Infection","enrollment":850},{"nctId":"NCT05137236","phase":"PHASE2","title":"A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Vaccine Boosters","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2021-12-06","conditions":"SARS-CoV-2","enrollment":540},{"nctId":"NCT05973006","phase":"PHASE3","title":"Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines","status":"COMPLETED","sponsor":"Novavax","startDate":"2023-08-16","conditions":"COVID-19","enrollment":400},{"nctId":"NCT06097273","phase":"PHASE3","title":"A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-10-19","conditions":"SARS-CoV-2, Influenza","enrollment":8061},{"nctId":"NCT06147063","phase":"PHASE1","title":"A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-11-27","conditions":"COVID-19, SARS-CoV-2 Infection","enrollment":243},{"nctId":"NCT05875701","phase":"PHASE3","title":"Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines","status":"COMPLETED","sponsor":"Novavax","startDate":"2023-03-28","conditions":"COVID-19","enrollment":147},{"nctId":"NCT04930770","phase":"PHASE2","title":"Study About the Response to the Administration of a Third Dose of mRNA-1273 Vaccine (COVID-19 Vaccine Moderna) in Renal Transplants With Immunological Failure Initial to Vaccination","status":"WITHDRAWN","sponsor":"Maria Joyera Rodríguez","startDate":"2021-09","conditions":"Covid19","enrollment":""},{"nctId":"NCT04796896","phase":"PHASE2, PHASE3","title":"A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2021-03-15","conditions":"SARS-CoV-2","enrollment":11942},{"nctId":"NCT06020118","phase":"PHASE4","title":"Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations","status":"COMPLETED","sponsor":"Duke University","startDate":"2023-09-25","conditions":"Influenza, COVID-19","enrollment":455},{"nctId":"NCT06743334","phase":"","title":"Secondary Databased Post-marketing Surveillance Study of BNT162b2","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-04-23","conditions":"COVID-19, SARS-CoV-2","enrollment":1},{"nctId":"NCT05321407","phase":"","title":"COVID-19 Vaccine Responses in PIDD Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Duke University","startDate":"2021-09-30","conditions":"X-linked Agammaglobulinemia, XLA, Primary Immune Deficiency","enrollment":100},{"nctId":"NCT05525208","phase":"PHASE2","title":"Booster Study of COVID-19 Protein Subunit Recombinant Vaccine","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2022-09-01","conditions":"COVID-19","enrollment":696},{"nctId":"NCT05972993","phase":"PHASE1","title":"A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-08-07","conditions":"COVID-19","enrollment":114},{"nctId":"NCT05933304","phase":"","title":"A Study of the Effectiveness of Moderna COVID-19 Vaccine","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2020-12-18","conditions":"SARS-CoV-2, COVID-19","enrollment":927004},{"nctId":"NCT06354998","phase":"PHASE3","title":"A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-04-08","conditions":"SARS-CoV-2","enrollment":217},{"nctId":"NCT05621239","phase":"","title":"A Study to Understand is the COVID-19 Vaccine BNT162b2 is Safe in Indonesia People","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-03-15","conditions":"COVID-19","enrollment":260},{"nctId":"NCT05160766","phase":"PHASE2","title":"Assessing Immune Response of Different COVID-19 Vaccines in Older Adults","status":"COMPLETED","sponsor":"Oliver Cornely, MD","startDate":"2021-11-08","conditions":"Prevention of COVID-19","enrollment":323},{"nctId":"NCT04878211","phase":"PHASE4","title":"A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-06-10","conditions":"Relapsing Multiple Sclerosis (RMS)","enrollment":24},{"nctId":"NCT04869358","phase":"PHASE4","title":"Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With Ofatumumab","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-05-27","conditions":"Relapsing Multiple Sclerosis","enrollment":34},{"nctId":"NCT04776317","phase":"PHASE1","title":"Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-03-25","conditions":"COVID-19","enrollment":81},{"nctId":"NCT05197621","phase":"","title":"The Impact of COVID-19 on Maternal and Neonatal Outcomes","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2020-04-13","conditions":"COVID-19, Pregnancy; Infection","enrollment":300},{"nctId":"NCT06761612","phase":"","title":"Retail COVID-19 Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biomedical Advanced Research and Development Authority","startDate":"2024-10-19","conditions":"COVID - 19","enrollment":2660},{"nctId":"NCT05815498","phase":"PHASE3","title":"A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-03-28","conditions":"COVID-19","enrollment":14246},{"nctId":"NCT06255626","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2024-05-27","conditions":"COVID-19","enrollment":215},{"nctId":"NCT04889209","phase":"PHASE1, PHASE2","title":"Delayed Heterologous SARS-CoV-2 Vaccine Dosing (Boost) After Receipt of EUA Vaccines","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-05-28","conditions":"COVID-19","enrollment":867},{"nctId":"NCT06919796","phase":"PHASE2","title":"mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes","status":"NOT_YET_RECRUITING","sponsor":"PharmaJet, Inc.","startDate":"2025-05-01","conditions":"Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers, SARS CoV-2","enrollment":40},{"nctId":"NCT05067933","phase":"PHASE2","title":"A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine","status":"TERMINATED","sponsor":"Vaxart","startDate":"2021-10-22","conditions":"COVID-19","enrollment":66},{"nctId":"NCT05359250","phase":"","title":"Myocardial Injury and Dysfunction Associated With COVID-19 Vaccination","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2021-05-12","conditions":"Myocardial Injury, COVID-19, Vaccine Reaction","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4258,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"COVID19 mRNA vaccine","genericName":"COVID19 mRNA vaccine","companyName":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","companyId":"fondazione-irccs-ca-granda-ospedale-maggiore-policlinico","modality":"Biologic","firstApprovalDate":"","aiSummary":"The COVID19 mRNA vaccine works by instructing cells to produce a piece of a viral protein, triggering an immune response to the virus. Used for Prevention of COVID-19 disease caused by SARS-CoV-2 virus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}